Cambiogenplasmid (neovasculgen) Report issue

Active Ingredient History

NOW
  • Now
Cambiogenplasmid, marketed as Neovasculgen, is a gene therapy drug for treatment of peripheral artery disease, including critical limb ischemia; it delivers the gene encoding for vascular endothelial growth factor (VEGF). Neovasculogen is a plasmid encoding the CMV promoter and the 165 amino acid form of VEGF. It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.   Wikipedia

More Chemistry
neovasculgen

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue